A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Summary

This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the safety profile of AC676 * Evaluate the pharmacokinetics of AC676 * Evaluate the effectiveness of AC676

Timeline

Start

2023-06-20

Primary completion

2026-03-31

Completion

2026-05-31

Drugs

Indications